NCT04800081 is a NA clinical trial of Sacubitril/Valsartan in Hypertension, sponsored by LanZhou University.

Who is sponsoring NCT04800081?

NCT04800081 is sponsored by LanZhou University.

What drugs are being tested in NCT04800081?

Interventions in NCT04800081: Sacubitril/Valsartan, Valsartan.

What condition does NCT04800081 study?

NCT04800081 studies Hypertension.

Is NCT04800081 still recruiting?

NCT04800081 is currently status unknown. Last updated 16 March 2021.

Last reviewed 2021-03-16 · How we verify

NCT04800081

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of LCZ696 on Urinary Microalbumin and Pulse Wave Velocity in Perimenopausal Patients With Hypertension

Status unknown NA Last updated 16 March 2021

What this trial tests

NA trial testing Sacubitril/Valsartan in Hypertension in 264 participants. Status unknown.

Timeline

9 July 2020

Primary endpoint
9 June 2021

9 July 2021

Quick facts

Lead sponsor	LanZhou University
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	264
Start date	9 July 2020
Primary completion	9 June 2021
Estimated completion	9 July 2021
Sites	1 location across China

Drugs / interventions tested

Sacubitril/Valsartan
Valsartan (VALSARTAN) — full drug profile →

Conditions studied

Hypertension — all drugs for Hypertension →

Sponsor

LanZhou University

Who can join

Adults 40 to 60, female only, with Hypertension. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To explore the efficacy of Sacubitril/Valsartan in the treatment of perimenopausal hypertensive patients, as well as the difference between the antihypertensive efficacy and valsartan, the therapeutic effect of its exposure to different factors and the protection of target organs.To provide reference for the clinical treatment of perimenopausal hypertension patients with shakubactrivalsartan. 1. To evaluate the effects of Sacubitril/Valsartan on urinary microalbumin and pulse wave velocity in perimenopausal hypertension patients. 2. To evaluate the clinical application of Sacubitril/Valsartan in the treatment of perimenopausal hypertension, so as to improve the blood pressure management ability and control rate of patients with such hypertension.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Effect of sacubitril/valsartan or valsartan on ventricular remodeling and myocardial fibrosis in perimenopausal women with hypertension.
Chen J, Pei Y, Wang Q, Li C, et al · · 2023 · cited 9× · PMID 37071432 · DOI 10.1097/hjh.0000000000003430

Verify or expand the search:

Other trials of Sacubitril/Valsartan

Trials testing the same drug.

NCT07192341 — Sacubitril/Valsartan in Patients With Prosthetic Heart Valves With Heart Failure and Reduced Ejection Fraction · NA · recruiting
NCT06501651 — Sacubitril/Valsartan Treats Patients With Essential Hypertension and Type 2 Diabetic Nephropathy · Phase 4 · not yet recruiting
NCT05448872 — Real World Experience in Heart Failure With Reduced Ejection Fraction (HFrEF) Patients Treated With sAc/vaL. · completed
NCT04736433 — Replication of the PARADIGM-HF Heart Failure Trial in Healthcare Claims Data. · completed
NCT05243199 — Sacubitril/Valsartan for CKD5 Stage Dialysis Patients · Phase 4 · completed

Other recruiting trials for Hypertension

Currently open trials in the same condition.

NCT07413159 — The "Check, Monitor, Control Hypertension" Study is a 24-month Randomized Trial in Houston Targeting African Americans A · NA · recruiting
NCT07361276 — Observational Study That Will Evaluate Treatment Patterns in the Management of Hypertension in the Public Primary Care S · recruiting
NCT07238556 — A Novel Digital Tool Physicians Can Use to Prescribe Exercise to Patients With Cardiovascular Disease Risk Factors · NA · recruiting
NCT07238400 — Cardiac Effects of Mineralocorticoid Receptor Antagonism After Preeclampsia · Phase 2 · recruiting
NCT07135505 — Early Time-Restricted Eating in Older Adults With Hypertension · NA · recruiting

Other LanZhou University trials

Trials by the same sponsor.

NCT07312370 — Esomeprazole Plus Sucralfate for Post-ESD Ulcer Healing · Phase 4 · not yet recruiting
NCT07263867 — Enhanced Ward Rounds for Bowel Preparation Quality in Hospitalized Patients Undergoing Colonoscopy · NA · not yet recruiting
NCT07314554 — Recurrence After Gastric and Intestinal Polyp Resection · not yet recruiting
NCT07286877 — Enhanced Ward Rounds and Communication for Pre-procedural Anxiety in GI Endoscopy Patients · NA · not yet recruiting
NCT07234344 — A Predictive Model for Midwives' C F: A Cross-Sectional Study · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04800081 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by LanZhou University
Last refreshed: 16 March 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04800081.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing